265 related articles for article (PubMed ID: 2908530)
1. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
2. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
3. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
4. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
6. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
7. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
8. Development of acellular pertussis vaccines.
Sato Y; Sato H
Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185
[TBL] [Abstract][Full Text] [Related]
9. Japanese clinical trials with Takeda acellular pertussis vaccine.
Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
[TBL] [Abstract][Full Text] [Related]
10. Effect of heptakis (2,6-0-dimethyl)beta-cyclodextrin on cell growth and the production of pertussis toxin and filamentous hemagglutinin in Bordetella pertussis.
Suzuki Y; Imaizumi A; Ginnaga A; Sato H; Sato Y
Dev Biol Stand; 1985; 61():89-92. PubMed ID: 2872134
[TBL] [Abstract][Full Text] [Related]
11. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
12. The purification and characterization of an acellular pertussis vaccine.
Chazono M; Yoshida I; Konobe T; Fukai K
J Biol Stand; 1988 Apr; 16(2):83-9. PubMed ID: 2897370
[TBL] [Abstract][Full Text] [Related]
13. [Properties of an acellular preparation of Bordetella pertussis and its analysis after centrifugation in saccharose gradient].
Letowska I; Kaczurba E; Schiller B
Med Dosw Mikrobiol; 1993; 45(3):289-94. PubMed ID: 8189799
[TBL] [Abstract][Full Text] [Related]
14. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
15. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
16. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
Sato Y; Sato H
Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
[TBL] [Abstract][Full Text] [Related]
17. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
Sato Y; Sato H
Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
[TBL] [Abstract][Full Text] [Related]
18. Rapid purification of pertussis toxin (PT) and filamentous hemagglutinin (FHA) by cation-exchange chromatography.
Ozcengiz E; Kilinç K; Büyüktanir O; Günalp A
Vaccine; 2004 Mar; 22(11-12):1570-5. PubMed ID: 15063583
[TBL] [Abstract][Full Text] [Related]
19. Comparative biological activities of acellular pertussis vaccines produced by Kitasato.
Watanabe M; Izumiya K; Sato T; Yoshino K; Nakagawa N; Ohoishi M; Hoshino M
Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236
[TBL] [Abstract][Full Text] [Related]
20. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
Alonso S; Pethe K; Mielcarek N; Raze D; Locht C
Infect Immun; 2001 Oct; 69(10):6038-43. PubMed ID: 11553541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
